Collins Helen Louise 4
4 · Enliven Therapeutics, Inc. · Filed Apr 15, 2024
Insider Transaction Report
Form 4
Collins Helen Louise
CHIEF MEDICAL OFFICER
Transactions
- Exercise/Conversion
Common Stock
2024-04-11$2.48/sh+20,000$49,600→ 20,000 total - Exercise/Conversion
Stock Option (right to buy)
2024-04-11−20,000→ 267,084 totalExercise: $2.48Exp: 2031-06-17→ Common Stock (20,000 underlying) - Sale
Common Stock
2024-04-11$25.07/sh−20,000$501,478→ 0 total
Footnotes (3)
- [F1]The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023.
- [F2]This transaction was executed in multiple trades at prices ranging from $25.00 to $25.49. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F3]The option, originally for 287,084 shares, vested as to one-fourth of the shares on June 17, 2022, and the remainder vest in 36 equal monthly installments thereafter.